Access the resources below for additional details about RUKOBIA, including the challenges of people living with multidrug-resistant (MDR) HIV-1 who are failing their current therapy, its mechanism of action, information about the BRIGHTE trial, dosing and drug interactions, and the full Prescribing Information.
BRIGHTE Long-Term Data for RUKOBIA
~5-Year* Efficacy Results
Hear from Dr. Tony Mills on the exciting long-term data for RUKOBIA
BRIGHTE Educational Series
INTRODUCTION TO PEOPLE LIVING WITH MDR HIV-1
Consider challenges faced by people living with multidrug-resistant (MDR) HIV-1 with multidrug resistance and limited antiretroviral (ARV) options
NOVEL MECHANISM OF ACTION
Discover a first-in-class attachment inhibitor that prevents HIV-1 from interacting with host immune cells1
DOSING AND DRUG INTERACTIONS
Review recommended dosing, considerations for coadministration, and contraindications with RUKOBIA
- Cahn P, Fink V, Patterson P. Fostemsavir: a new CD4 attachment inhibitor. Curr Opin HIV AIDS. 2018;13(4):341-345.